A small study finds potential hope in the treatment of COVID 19.
Inpatients with COVID-19 who received an inhaled form of interferon beta, a drug that is often used in an injected form to treat conditions such as multiple sclerosis, had a 79 percent lower risk of developing more debilitating symptoms that could lead to Ventilation or death, according to study results announced Monday by British company Synairgen.
Patients who received the drug, known as SNG001, were also twice as likely to recover compared to those who received a placebo.
WEST NILE VIRUS SURPASSED DURING THE CORONAVIRUS PANDEMIC? PUBLIC HEALTH EXPERT APPOINTS SIMILAR SYMPTOMS
“We are all delighted with the results of the trial.” Marsden says the results “showed that SNG001 greatly reduced the number of patients hospitalized with COVID-19 who progressed from ‘requiring oxygen’ to ‘requiring ventilation,'” company CEO Richard Marsden said in a statement from press.
The double-blind, placebo-controlled study, which has not been published in a peer-reviewed journal, also found that patients who received the inhaled medication were twice as likely to return to their regular daily activities without limitation and their average length of stay. hospital was reduced from 9 days to 6 days. The statement also indicates that patients had fewer complaints of dyspnea, a common symptom in those with COVID-19. The study included 101 patients.
THE UNIFORM USE OF CORONAVIRUS FACE MASKS MAY HAVE PREVENTED BRUTE IN THE MISSOURI HAIR SALON: REPORT
One of the trial’s researchers, Tom Wilkinson, a professor of respiratory medicine at the University of Southampton, explained that interferon beta “has enormous potential as an inhaled medication to restore the lung’s immune response, improve protection, speed recovery, and counteract the impact of the SARS-CoV-2 virus. “
The researchers in the study say that SARS-VOC-2 attacks the lung’s initial ability to fight a virus. Stephen Holgate, one of the co-founders of Synairgen, clinical professor of immunopharmacology at the University of Southampton Medical Research Council, says in the statement, “Our inhaled treatment of giving high local concentrations of interferon beta, a natural antiviral protein, restores the ability of the lung. ” to neutralize the virus, or any virus mutation, or coinfection with another respiratory virus such as influenza or RSV, as might be found in the winter if there is a resurgence of COVID-19. “
CLICK HERE TO GET THE FOX NEWS APP
“This evaluation of SNG001 in patients with COVID-19 could indicate an important advance in the treatment of hospitalized patients with COVID-19. Our efforts now focus on working with regulators and other key groups to advance this possible COVID-19 treatment as quickly as possible, “said Marsden.
As of Tuesday afternoon, there were more than 3.8 million infections and at least 141,426 deaths from COVID-19 in the United States.
